Łukasz Zyskowski
4 Papers
4 Citations
Łukasz Zyskowski is an academic researcher. The author has contributed to research in topics: Gene & Genome-wide association study. The author has co-authored 4 publications.
Chat about Author
Papers
GWAS Links New Variant in Long Non-Coding RNA LINC02006 with Colorectal Cancer Susceptibility.
Ewa E. Hennig,Anna Kluska,Magdalena Piątkowska,Maria Kulecka,Aneta Balabas,Natalia Zeber-Lubecka,Krzysztof Goryca,Filip Ambrozkiewicz,Jakub Karczmarski,Tomasz Olesiński,Łukasz Zyskowski,Jerzy Ostrowski +11 more
TL;DR: In this paper, a pooled DNA samples-based GWAS was conducted in search of genetic variants associated with colorectal cancer (CRC) in a Polish population, including 465 CRC patients and 1548 controls, and the discovered loci were found to explain 10% of the overall risk of developing CRC.
7
Diagnostics and treatment of small intestine tumors in our own experience
Łukasz Zyskowski,Piotr Surowski,Andrzej Rutkowski,Paulina Wieszczy,Joanna Milewska,Tomasz Olesiński +5 more
TL;DR: A retrospective analysis of 54 patients undergoing surgery for small intestine tumor in the years 2006–2015 found that partial resection of the small intestine remains the basic method of radical surgical treatment.
Metastatic tumors of pancreas — whether and when surgical intervention is gainful for diseased people. Retrospective analysis of data from three surgery centers
Ireneusz Pierzankowski,Mariusz Bednarczyk,Adam Dmitruk,P Hevelke,Tomasz Maj,Piotr Saramak,Piotr Surowski,Marek Szpakowski,Leszek Zając,Łukasz Zyskowski,Jakub Pałucki,Andrzej Krajewski,Marek Wroński,Maciej Słodkowski,Eryk Chrapowicki,Andrzej Cichocki,Maria Zwierko,Tomasz Olesiński +17 more
TL;DR: The main factor that determines the patient’s future fate is the type of primary neoplasm and surgical treatment of metastatic tumors in the pancreas is the best solution for selected RCC cases.
Long-term results of randomized studies on the use of a gentamicin-collagen sponge in rectal cancer – depending on the length of time between the completion of radiotherapy and the surgery
TL;DR: The use of GRM decreases the risk of distant metastases and has an influence on the prolongation of recurrence free survival, but only when surgery is carried out within 7 days of the completion of irradiation.